Trius Therapeutics Inc. (TSRX) Friday said it has obtained a committed equity financing facility under which it may from time to time sell up to $25 million of its registered common stock to Terrapin Opportunity L.P., over a 24-month period.
Trius is not obligated to utilize any of the $25 million facility and remains free to enter into and consummate other equity and debt financing transactions.
"This facility, combined with Trius' nearly $84 million in cash and investments at June 30, 2012, provides Trius with additional financing options as the Company prepares for the commercialization of tedizolid phosphate," said John Schmid, Chief Financial Officer of Trius.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.